TY - JOUR
T1 - Laboratory based assessment of gait and balance impairment in patients with progressive supranuclear palsy
AU - Ali, Farwa
AU - Loushin, Stacy R.
AU - Botha, Hugo
AU - Josephs, Keith A.
AU - Whitwell, Jennifer L.
AU - Kaufman, Kenton
N1 - Funding Information:
NINDS R01 NS89757 and Internal Neurology Departmental small grant part of UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS).
Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/10/15
Y1 - 2021/10/15
N2 - Background: Gait and balance abnormalities are a significant source of morbidity and mortality in progressive supranuclear palsy (PSP). Gait impairment in PSP is primarily assessed clinically on exam or with the use of rating scales. Three dimensional video based gait and balance analysis performed in a laboratory setting is a highly accurate method of motion analysis (Wren et al., 2020), however limited data is available in patients with PSP. Research question: In this study we assess the objective features of postural control, kinematics, kinetic and temporal-spatial gait metrics in PSP, using three-dimensional video motion analysis in a laboratory setting compared to normal controls. Methods: Three-dimensional motion was captured using a 10-camera motion capture system, 41 body markers and ground embedded force plates in 16 patients with PSP patients and compared to motorically normal controls. Results: Spatiotemporal, kinematic, and kinetic gait measures effectively differentiated patients with PSP from controls. Patients had slower gait velocity, lower cadence, increased double support time and abnormal antero-posterior sway. Joint kinematics and kinetics were reduced and showed less variation among patients with PSP compared to controls which is suggestive of bradykinesia. Objective gait measures of abnormality correlated with clinical disease severity. Postural sway metrics distinguished PSP from controls and captured gait imbalance. Significance: Objective measures of gait and balance abnormalities in patients with PSP provide an outcome measure that can be potentially used for early disease detection, in clinical trials and to validate portable motion capture devices in the future.
AB - Background: Gait and balance abnormalities are a significant source of morbidity and mortality in progressive supranuclear palsy (PSP). Gait impairment in PSP is primarily assessed clinically on exam or with the use of rating scales. Three dimensional video based gait and balance analysis performed in a laboratory setting is a highly accurate method of motion analysis (Wren et al., 2020), however limited data is available in patients with PSP. Research question: In this study we assess the objective features of postural control, kinematics, kinetic and temporal-spatial gait metrics in PSP, using three-dimensional video motion analysis in a laboratory setting compared to normal controls. Methods: Three-dimensional motion was captured using a 10-camera motion capture system, 41 body markers and ground embedded force plates in 16 patients with PSP patients and compared to motorically normal controls. Results: Spatiotemporal, kinematic, and kinetic gait measures effectively differentiated patients with PSP from controls. Patients had slower gait velocity, lower cadence, increased double support time and abnormal antero-posterior sway. Joint kinematics and kinetics were reduced and showed less variation among patients with PSP compared to controls which is suggestive of bradykinesia. Objective gait measures of abnormality correlated with clinical disease severity. Postural sway metrics distinguished PSP from controls and captured gait imbalance. Significance: Objective measures of gait and balance abnormalities in patients with PSP provide an outcome measure that can be potentially used for early disease detection, in clinical trials and to validate portable motion capture devices in the future.
KW - Balance
KW - Falls
KW - Gait
KW - Motion analysis
KW - Progressive supranuclear palsy
UR - http://www.scopus.com/inward/record.url?scp=85113667976&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85113667976&partnerID=8YFLogxK
U2 - 10.1016/j.jns.2021.118054
DO - 10.1016/j.jns.2021.118054
M3 - Article
C2 - 34461552
AN - SCOPUS:85113667976
SN - 0022-510X
VL - 429
JO - Journal of the neurological sciences
JF - Journal of the neurological sciences
M1 - 118054
ER -